uniQure N.V. Revenue from Contract with Customer, Including Assessed Tax
uniQure N.V. (QURE) reported Revenue from Contract with Customer, Including Assessed Tax of $16.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2026-03-02
- uniQure N.V. revenue from contract with customer, including assessed tax for the quarter ending 2025-12-31 was $5.57M, a 6.65% increase year-over-year.
- uniQure N.V. revenue from contract with customer, including assessed tax for the quarter ending 2025-09-30 was $3.70M, a 61.83% increase year-over-year.
- uniQure N.V. revenue from contract with customer, including assessed tax for the quarter ending 2025-06-30 was $5.26M, a 52.71% decline year-over-year.
- uniQure N.V. revenue from contract with customer, including assessed tax for the quarter ending 2025-03-31 was $1.57M, a 81.53% decline year-over-year.
- uniQure N.V. revenue from contract with customer, including assessed tax for fiscal 2025 was $16.10M, a 40.64% decline from fiscal 2024.
- uniQure N.V. revenue from contract with customer, including assessed tax for fiscal 2024 was $27.12M, a 71.17% increase from fiscal 2023.
- uniQure N.V. revenue from contract with customer, including assessed tax for fiscal 2023 was $15.84M, a 85.12% decline from fiscal 2022.
- uniQure N.V. revenue from contract with customer, including assessed tax for fiscal 2022 was $106.48M, a 79.68% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $5.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $9.27M derived: sum of 2 quarters · filed 2026-03-02 | $14.53M derived: sum of 3 quarters · filed 2026-03-02 | $16.10M 10-K · filed 2026-03-02 |
| 2025-09-30 | $3.70M 10-Q · filed 2025-11-10 | $8.96M derived: sum of 2 quarters · filed 2025-11-10 | $10.53M 10-Q · filed 2025-11-10 | $15.75M derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-06-30 | $5.26M 10-Q · filed 2025-07-29 | $6.83M 10-Q · filed 2025-07-29 | $12.05M derived: sum of 3 quarters · filed 2026-03-02 | $14.34M derived: sum of 4 quarters · filed 2026-03-02 |
| 2025-03-31 | $1.57M 10-Q · filed 2025-05-09 | $6.79M derived: sum of 2 quarters · filed 2026-03-02 | $9.07M derived: sum of 3 quarters · filed 2026-03-02 | $20.20M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-12-31 | $5.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $7.51M derived: sum of 2 quarters · filed 2026-03-02 | $18.63M derived: sum of 3 quarters · filed 2026-03-02 | $27.12M 10-K · filed 2026-03-02 |
| 2024-09-30 | $2.29M 10-Q · filed 2025-11-10 | $13.41M derived: sum of 2 quarters · filed 2025-11-10 | $21.90M 10-Q · filed 2025-11-10 | $28.59M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $11.13M 10-Q · filed 2025-07-29 | $19.61M 10-Q · filed 2025-07-29 | $26.30M derived: sum of 3 quarters · filed 2026-03-02 | $27.71M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $8.48M 10-Q · filed 2025-05-09 | $15.17M derived: sum of 2 quarters · filed 2026-03-02 | $16.58M derived: sum of 3 quarters · filed 2026-03-02 | $19.00M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $6.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $8.10M derived: sum of 2 quarters · filed 2026-03-02 | $10.52M derived: sum of 3 quarters · filed 2026-03-02 | $15.84M 10-K · filed 2026-03-02 |
| 2023-09-30 | $1.41M 10-Q · filed 2024-11-05 | $3.83M derived: sum of 2 quarters · filed 2024-11-05 | $9.15M 10-Q · filed 2024-11-05 | $111.90M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $2.42M 10-Q · filed 2024-08-01 | $7.75M 10-Q · filed 2024-08-01 | $110.49M derived: sum of 3 quarters · filed 2025-02-27 | $111.94M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $5.33M 10-Q · filed 2024-05-07 | $108.07M derived: sum of 2 quarters · filed 2025-02-27 | $109.52M derived: sum of 3 quarters · filed 2025-02-27 | $110.02M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $102.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $104.19M derived: sum of 2 quarters · filed 2025-02-27 | $104.69M derived: sum of 3 quarters · filed 2025-02-27 | $106.48M 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.45M 10-Q · filed 2023-11-07 | $1.95M derived: sum of 2 quarters · filed 2023-11-07 | $3.74M 10-Q · filed 2023-11-07 | $61.43M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $497.00K 10-Q · filed 2023-08-01 | $2.29M 10-Q · filed 2023-08-01 | $59.98M derived: sum of 3 quarters · filed 2024-02-28 | $61.97M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $1.79M 10-Q · filed 2023-05-09 | $59.48M derived: sum of 2 quarters · filed 2024-02-28 | $61.47M derived: sum of 3 quarters · filed 2024-02-28 | $525.34M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $57.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $59.68M derived: sum of 2 quarters · filed 2024-02-28 | $523.55M derived: sum of 3 quarters · filed 2024-02-28 | $524.00M 10-K · filed 2024-02-28 |
| 2021-09-30 | $1.99M 10-Q · filed 2022-11-02 | $465.86M derived: sum of 2 quarters · filed 2022-11-02 | $466.31M 10-Q · filed 2022-11-02 | $500.40M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $463.87M 10-Q · filed 2022-08-08 | $464.32M 10-Q · filed 2022-08-08 | $498.41M derived: sum of 3 quarters · filed 2023-02-27 | $500.20M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $454.00K 10-Q · filed 2022-05-02 | $34.54M derived: sum of 2 quarters · filed 2023-02-27 | $36.33M derived: sum of 3 quarters · filed 2023-02-27 | $37.86M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $34.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $35.88M derived: sum of 2 quarters · filed 2023-02-27 | $37.41M derived: sum of 3 quarters · filed 2023-02-27 | $37.51M 10-K · filed 2023-02-27 |
| 2020-09-30 | $1.79M 10-Q · filed 2021-10-25 | $3.32M derived: sum of 2 quarters · filed 2021-10-25 | $3.43M 10-Q · filed 2021-10-25 | $6.05M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $1.53M 10-Q · filed 2021-07-26 | $1.64M 10-Q · filed 2021-07-26 | $4.26M derived: sum of 3 quarters · filed 2022-02-25 | $5.31M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $104.00K 10-Q · filed 2021-05-10 | $2.73M derived: sum of 2 quarters · filed 2022-02-25 | $3.77M derived: sum of 3 quarters · filed 2022-02-25 | $6.25M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $2.63M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $3.67M derived: sum of 2 quarters · filed 2022-02-25 | $6.14M derived: sum of 3 quarters · filed 2022-02-25 | $7.28M 10-K · filed 2022-02-25 |
| 2019-09-30 | $1.05M 10-Q · filed 2020-10-27 | $3.52M derived: sum of 2 quarters · filed 2020-10-27 | $4.66M 10-Q · filed 2020-10-27 | $6.26M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $2.47M 10-Q · filed 2020-07-30 | $3.61M 10-Q · filed 2020-07-30 | $5.22M derived: sum of 3 quarters · filed 2021-03-01 | $8.37M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $1.14M 10-Q · filed 2020-04-29 | $2.74M derived: sum of 2 quarters · filed 2021-03-01 | $5.89M derived: sum of 3 quarters · filed 2021-03-01 | $8.94M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $4.76M derived: sum of 2 quarters · filed 2021-03-01 | $7.81M derived: sum of 3 quarters · filed 2021-03-01 | $11.28M 10-K · filed 2021-03-01 |
| 2018-09-30 | $3.15M 10-Q · filed 2019-10-28 | $6.20M derived: sum of 2 quarters · filed 2019-10-28 | $9.68M 10-Q · filed 2019-10-28 | $12.26M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $3.05M 10-Q · filed 2019-07-29 | $6.53M 10-Q · filed 2019-07-29 | $9.11M derived: sum of 3 quarters · filed 2020-03-02 | $11.37M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $3.48M 10-Q · filed 2019-04-29 | $6.06M derived: sum of 2 quarters · filed 2020-03-02 | $8.32M derived: sum of 3 quarters · filed 2020-03-02 | $13.26M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $2.58M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $4.84M derived: sum of 2 quarters · filed 2020-03-02 | $9.79M derived: sum of 3 quarters · filed 2020-03-02 | $13.11M 10-K · filed 2020-03-02 |
| 2017-09-30 | $2.26M 10-Q · filed 2018-11-06 | $7.20M derived: sum of 2 quarters · filed 2018-11-06 | $10.52M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $4.94M 10-Q · filed 2018-08-08 | $8.26M 10-Q · filed 2018-08-08 | ||
| 2016-12-31 | $25.10M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |